首页> 外文期刊>BMC Cancer >High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining
【24h】

High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining

机译:使用集成了自动免疫荧光染色的双重技术平台对循环肿瘤细胞进行高回收率的视觉识别和单细胞检索,以进行基因组分析

获取原文
       

摘要

Background Circulating tumor cells (CTCs) are malignant cells that have migrated from solid cancers into the blood, where they are typically present in rare numbers. There is great interest in using CTCs to monitor response to therapies, to identify clinically actionable biomarkers, and to provide a non-invasive window on the molecular state of a tumor. Here we characterize the performance of the AccuCyte? – CyteFinder? system, a comprehensive, reproducible and highly sensitive platform for collecting, identifying and retrieving individual CTCs from microscopic slides for molecular analysis after automated immunofluorescence staining for epithelial markers. Methods All experiments employed a density-based cell separation apparatus (AccuCyte) to separate nucleated cells from the blood and transfer them to microscopic slides. After staining, the slides were imaged using a digital scanning microscope (CyteFinder). Precisely counted model CTCs (mCTCs) from four cancer cell lines were spiked into whole blood to determine recovery rates. Individual mCTCs were removed from slides using a single-cell retrieval device (CytePicker?) for whole genome amplification and subsequent analysis by PCR and Sanger sequencing, whole exome sequencing, or array-based comparative genomic hybridization. Clinical CTCs were evaluated in blood samples from patients with different cancers in comparison with the CellSearch? system. Results AccuCyte – CyteFinder presented high-resolution images that allowed identification of mCTCs by morphologic and phenotypic features. Spike-in mCTC recoveries were between 90 and 91%. More than 80% of single-digit spike-in mCTCs were identified and even a single cell in 7.5?mL could be found. Analysis of single SKBR3 mCTCs identified presence of a known TP53 mutation by both PCR and whole exome sequencing, and confirmed the reported karyotype of this cell line. Patient sample CTC counts matched or exceeded CellSearch CTC counts in a small feasibility cohort. Conclusion The AccuCyte – CyteFinder system is a comprehensive and sensitive platform for identification and characterization of CTCs that has been applied to the assessment of CTCs in cancer patient samples as well as the isolation of single cells for genomic analysis. It thus enables accurate non-invasive monitoring of CTCs and evolving cancer biology for personalized, molecularly-guided cancer treatment.
机译:背景技术循环肿瘤细胞(CTC)是已经从实体癌迁移到血液中的恶性细胞,在这些血液中它们通常很少见。使用CTC来监测对治疗的反应,识别临床上可操作的生物标志物以及提供关于肿瘤分子状态的非侵入性窗口非常令人感兴趣。在这里,我们表征AccuCyte的性能吗? – CyteFinder?系统,一个全面,可重现和高度敏感的平台,用于从上皮标记物进行自动免疫荧光染色后,从显微镜载玻片上收集,鉴定和检索单个CTC进行分子分析。方法所有实验均采用基于密度的细胞分离仪(AccuCyte)从血液中分离有核细胞,并将其转移至显微镜载玻片上。染色后,使用数字扫描显微镜(CyteFinder)对载玻片成像。将来自四个癌细胞系的精确计数的模型CTC(mCTC)掺入全血以确定恢复率。使用单细胞检索设备(CytePicker?)从载玻片上除去单个mCTC,以进行全基因组扩增,然后通过PCR和Sanger测序,全外显子组测序或基于阵列的比较基因组杂交进行分析。与CellSearch?相比,对来自不同癌症患者的血液样本中的临床CTC进行了评估。系统。结果AccuCyte – CyteFinder提供了高分辨率图像,可通过形态学和表型特征鉴定mCTC。尖峰型mCTC回收率在90%至91%之间。鉴定出超过80%的单数穗型mCTC,甚至可以找到7.5?mL的单个细胞。对单个SKBR3 mCTC的分析通过PCR和整个外显子组测序确定了已知的TP53突变的存在,并证实了该细胞系的报道的核型。在一个小的可行性研究队列中,患者样本CTC计数与CellSearch CTC计数匹配或超过。结论AccuCyte – CyteFinder系统是用于CTC鉴定和表征的全面而敏感的平台,已被用于评估癌症患者样品中的CTC以及分离用于基因组分析的单细胞。因此,它可以对CTC进行精确的非侵入性监测,并可以发展癌症生物学以进行个性化的分子指导的癌症治疗。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号